Bachem said it will invest CHF 500 million: what it means for Bachem stock

Published on 10/13/2026 at 00:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sisslerfeld needs more than CHF 500 million by 2030. For Bachem stock, 35-40 percent growth guidance follows CHF 326.4 million first-half 2026 sales.

Key points in brief

Bachem said it will invest more than CHF 500 million in the Sisslerfeld facility, with production expected in 2030.
First-half 2026 sales rose 4.00 percent to CHF 326.40 million, while the company guided for 35.00-40.00 percent growth in local currencies.
Bachem stock was last at EUR 86.73 at Lang & Schwarz on October 12, 2026, while SIX showed CHF 80.90 and a CHF 48.52-84.10 52-week range.
The next reported company date is the Capital Markets Day on November 26, 2026.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem said it will invest more than CHF 500 million in its Sisslerfeld production project, with commercial output expected in 2030, according to the company's July 30, 2026 earnings call published by Yahoo Finance. The project gives the peptide and oligonucleotide manufacturer a long-term capacity story, but the financial return is tied to construction and customer ramp-up through 2030.

What does the project mean?

The July 30 call put the investment beside a more immediate operating update. Bachem reported CHF 326.40 million in sales for the first half of 2026, up 4.00 percent from the first half of 2025, while sales growth in local currencies reached 7.30 percent, Yahoo Finance reported from the call.

The capacity plan is already absorbing capital. Bachem invested CHF 148.00 million in the first six months of 2026 and set full-year capital expenditure guidance at CHF 350.00 million to CHF 400.00 million. Management also said all orders for the remaining part of 2026 were already in the books.

Growth guidance narrows

Management expects 2026 sales to grow 35.00-40.00 percent in local currencies, compared with earlier guidance of 35.00-45.00 percent. The earnings call said the narrower range reflects better visibility on the production schedule rather than a change in the company's strategic direction.

Profitability remains linked to execution. Bachem reported a 25.40 percent EBITDA margin for the first half of 2026, down from 25.90 percent in local currency, while first-half operating cash flow reached CHF 104.70 million. The figures show the trade-off investors are watching: capacity spending is intended to support growth, while commissioning costs weigh on the near-term margin.

Three dated company milestones

On July 21, 2026, Bachem outlined plans for a large-scale Sisslerfeld production facility requiring more than CHF 500 million, as reflected in the company coverage summarized by Pharma Manufacturing. On July 30, 2026, Bachem reported CHF 326.40 million in first-half sales and 35.00-40.00 percent full-year growth guidance, according to Yahoo Finance. On September 23, 2026, Pharma Manufacturing linked the Sisslerfeld build-out to demand for peptide active ingredients and GLP-1 therapies.

What dates come next?

Bachem's next substantiated company date is the Capital Markets Day on November 26, 2026, stated during the July 30 earnings call. The next expected reporting date is March 4, 2027, when Bachem is scheduled to present fourth-quarter 2026 results, according to finanzen.ch.

Stock stays below its yearly high

On SIX, Bachem was last at CHF 80.90 on October 12, 2026 at 5:30 p.m. CEST. The stock's 52-week range was CHF 48.52 to CHF 84.10, leaving the SIX price CHF 3.20 below its high. The latest Lang & Schwarz quote was EUR 86.73 on October 12, 2026 at 11:00 p.m. CEST, a dated last price for German investors.

Market context: Market report SMI.